The deal includes an undisclosed upfront payment from BMS, with GentiBio also in line to receive milestone payments of up to $1.9 billion, as well as royalties on any future sales. The partners ...
Although new U.S. tariffs on Canada, Mexico, and China are putting pressure on markets, investors are shifting toward ...
Pharmaceutical Technology on MSN4d
BMS to acquire longtime cell therapy partner 2seventy bio for $286mThe deal comes after a challenging few years for 2seventy bio, which had divested research programmes in recent years.
Bristol Myers Squibb buys 2seventy bio for $286 million, strengthening its cancer portfolio with Abecma CAR-T therapy for ...
Exscientia’s current clinical-stage pipeline consists of CDK7 inhibitor GTAEXS-617, which is co-owned with GT Apeiron, Evotec-partnered A2A receptor antagonist EXS-21546, and BMS-partnered PKC ...
NEW YORK – Bristol Myers Squibb and 2seventy Bio on Monday entered into a merger agreement in which BMS will acquire 2seventy for $286 million, ending the firms' cost-sharing agreement for the ...
The deal caps a turbulent three years for 2seventy bio. The company served as the oncology business of Bluebird Bio until Bluebird spun out 2seventy in 2021.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback